COMMUNIQUÉS West-GlobeNewswire

Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis
22/06/2026
The planned Phase 3 trial in approximately 750 postmenopausal women with osteoporosis, with a primary endpoint of total hip bone mineral density (BMD) at Month 12, would support Entera’s plan to submit a New Drug [...]
Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
22/06/2026
AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage : Multiple sclerosis (“MS”) robs people of control over their own bodies — slowly, relentlessly and without a cure. More than 2.9 million [...]
NewGen Issues 3,666,667 New Shares in Connection with Strategic K25.ai Acquisition, Reaches Milestone of US$7.6 Million Market Capitalization
22/06/2026
Strong Capitalization Foundation Supports Strategic Growth and Market Stability BANGKOK, June 22, 2026 (GLOBE NEWSWIRE) -- NewGenIVF Group Limited (Nasdaq: NIVF) (“NewGen” or the “Company”) today announced that NewGen’s [...]
Vivos Therapeutics and Streeterville Extend Timeframe of Strategic Financing Agreement and Reaffirm Commitment to Convert Debt Into Common Stock and Perpetual Preferred Equity
22/06/2026
LITTLETON, Colo., June 22, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment of breathing- [...]
Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts
22/06/2026
– Development Partner Torii Pharmaceutical also recently announced dosing of the first Japanese patient in this trial evaluating YCANTH (TO-208) in Japan – – Verrica maintains ownership of global rights to YCANTH for [...]
Clearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA‑Regulated Phase I/II Trial
22/06/2026
Vancouver, Canada, June 22, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel, non- [...]
TETmedical Receives FDA Breakthrough Device Designation for NSE-FAST®, the First Rapid Test Designed to Aid in the Diagnosis of Acute Ischemic Stroke
22/06/2026
FAIR HAVEN, N.J. and ITHACA, N.Y., June 22, 2026 (GLOBE NEWSWIRE) -- TETmedical, Inc., a clinical stage medical diagnostics company developing rapid tools for diagnosing acute neurological injury based on its patented [...]
BridgeBio to Present Primary Results from Phase 3 PROPEL 3 Trial of Oral Infigratinib for Children Living with Achondroplasia at ICCBH 2026
22/06/2026
PALO ALTO, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for [...]
Catheter Precision, Inc. Announces Allowance of Key Intellectual Property
22/06/2026
Eight New Patents Issued on Heart Failure Technology Three New Patents Granted on Vascular Closure Technology FORT MILL, S.C., June 22, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK: NYSE/American), today [...]
Prolium Bioscience Announces First Patient Dosed in its Multinational, Phase 1/2 Study of PRO-203 in Systemic Sclerosis, and Last Patient, Last Visit in an Investigator-Led Study of PRO-203 in Refractory Lupus Nephritis
22/06/2026
Phase 1/2 SSc study is expected to enroll patients at over 20 participating clinical sites in at least five countries Recently completed Phase 1 Single Ascending Dose study of PRO-203 in healthy volunteers Investigator- [...]
Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants
22/06/2026
The Breakthrough Therapy Designation (BTD) was granted based on the positive results from the EMBRAVE Part A trial of elsunersen Elsunersen demonstrated a 77% sham-adjusted reduction in monthly seizures (p=0.015), with [...]
Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome
22/06/2026
Completed dosing of 17 patients in REVEAL pivotal trial; topline data from 6 ‑ month interim analysis and FDA feedback on next steps toward BLA submission pathway expected 1H 2027 TSHA-102 was generally well-tolerated [...]
Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
22/06/2026
-- RMAT designation granted based on Phase 1/2 clinical data, including results previously published in The New England Journal of Medicine, demonstrating PM359’s potential to address unmet need in p47 phox -deficient [...]
Revolution Medicines Announces Planned Leadership Transition for Steve Kelsey, M.D.
22/06/2026
Steve Kelsey, president, R&D, to transition to senior advisor to CEO ahead of planned retirement in January 2027 Company announces new R&D leadership structure to support continued execution of strategy REDWOOD [...]
LifeMD Announces Exclusive Collaboration to Launch Direct-to-Patient Self-Pay Program for XYOSTED® (testosterone enanthate) Injection
22/06/2026
Landmark agreement between a leading virtual care company and a pharmaceutical manufacturer establishes an exclusive telehealth co-marketing arrangement with LifeMD for the XYOSTED self-pay program, launching in July [...]
Novel Key Terms For Managing CIDP Published in Neurology® Journal
22/06/2026
CONSHOHOCKEN, Pa., June 22, 2026 (GLOBE NEWSWIRE) -- The GBS|CIDP Foundation International is thrilled to announce the publication of shared key terms to describe the management of Chronic Inflammatory Demyelinating [...]
Route 92 Medical Announces First Commercial Cases in Canada
22/06/2026
Procedures follow Health Canada Medical Device License for the Company’s advanced neurovascular portfolio More than 100,000 patients suffer from strokes annually in Canada WEST JORDAN, Utah, June 22, 2026 (GLOBE [...]
Hyperion DeFi and Blockdaemon Partner to Expand Institutional Hyperliquid Staking Infrastructure
22/06/2026
DALLAS, June 22, 2026 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi” or the “Company”), the first U.S. publicly listed DeFi company building on Hyperliquid, today announced that it has partnered [...]
Atsena Therapeutics Doses First Patient and Reports Rapid Early Enrollment in Pivotal Trial of ATSN-201 for X-Linked Retinoschisis
22/06/2026
Enrollment expected to complete Q1 2027; topline results anticipated 1H 2028; BLA filing targeted for 2H 2028 Phase 1/2 data demonstrated ATSN-201's ability to reverse structural damage to the retina and improve vision [...]

Pages